Which statement about atropine use in ACLS is true?

Which statement about atropine use in ACLS is true?

• A. It has a maximum dose of 3 mg when patient has symptomatic bradycardia.
• B. It has detrimental effects during asystolic arrests.
• C. Administration should be followed by 5 cycles of CPR in PEA.
• D. All of the above.

Answer: (A)

In ACLS, atropine is used for symptomatic bradycardia to increase the heart rate by blocking parasympathetic (vagal) influence on the heart. The dosing is 0.5 mg IV every 3–5 minutes, with a total maximum dose of 3 mg. This makes the statement about a 3 mg maximum the correct one. For asystole or PEA, atropine is not routinely recommended because it does not improve outcomes in non-perfusing rhythms, so the idea that it has detrimental effects in arrest scenarios isn’t a standard ACLS assertion. Also, during a cardiac arrest the protocol emphasizes high-quality CPR and epinephrine every 3–5 minutes rather than a fixed sequence of CPR cycles after atropine. Therefore, the only true statement is the maximum dose for symptomatic bradycardia.

In ACLS, atropine is used for symptomatic bradycardia to increase the heart rate by blocking parasympathetic (vagal) influence on the heart. The dosing is 0.5 mg IV every 3–5 minutes, with a total maximum dose of 3 mg. This makes the statement about a 3 mg maximum the correct one. For asystole or PEA, atropine is not routinely recommended because it does not improve outcomes in non-perfusing rhythms, so the idea that it has detrimental effects in arrest scenarios isn’t a standard ACLS assertion. Also, during a cardiac arrest the protocol emphasizes high-quality CPR and epinephrine every 3–5 minutes rather than a fixed sequence of CPR cycles after atropine. Therefore, the only true statement is the maximum dose for symptomatic bradycardia.